Polar Capital Holdings Plc Increases Holdings in Dianthus Therapeutics, Inc. $DNTH

Polar Capital Holdings Plc boosted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,004,728 shares of the company’s stock after purchasing an additional 256,725 shares during the period. Polar Capital Holdings Plc owned approximately 2.32% of Dianthus Therapeutics worth $41,405,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares in the last quarter. Patient Square Capital LP acquired a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $4,919,000. UBS Group AG lifted its position in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares in the last quarter. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics in the 4th quarter worth approximately $765,000. Finally, Fairmount Funds Management LLC boosted its holdings in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ryan Savitz sold 114,367 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 149,121 shares of company stock worth $12,635,454 over the last quarter. 3.02% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, Wedbush upped their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Down 4.4%

DNTH stock opened at $78.88 on Wednesday. The stock’s 50 day moving average is $86.88 and its two-hundred day moving average is $65.73. Dianthus Therapeutics, Inc. has a 52-week low of $16.64 and a 52-week high of $96.50. The company has a market capitalization of $4.31 billion, a PE ratio of -19.10 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.